ABBOTT LABORATORIES Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
ABBOTT LABORATORIES (ABT) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $18.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-20
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2011-12-31 was $147.00M.
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2011-09-30 was $0.00.
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $18.00M, a 38.46% increase from fiscal 2024.
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $13.00M, a 90.97% decline from fiscal 2023.
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $144.00M.
- ABBOTT LABORATORIES unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2021 was $35.00M, a 29.63% increase from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 9 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $18.00M 10-K · filed 2026-02-20 | |||
| 2024-12-31 | $13.00M 10-K · filed 2026-02-20 | |||
| 2023-12-31 | $144.00M 10-K · filed 2024-02-16 | |||
| 2021-12-31 | $35.00M 10-K · filed 2023-02-17 | |||
| 2020-12-31 | $27.00M 10-K · filed 2022-02-18 | |||
| 2019-12-31 | $32.00M 10-K · filed 2021-02-19 | |||
| 2018-12-31 | $91.00M 10-K · filed 2020-02-21 | |||
| 2017-12-31 | $57.00M 10-K · filed 2019-02-22 | |||
| 2016-12-31 | $9.00M 10-K · filed 2018-02-16 | |||
| 2015-12-31 | $125.00M 10-K · filed 2017-02-17 | |||
| 2014-12-31 | $79.00M 10-K · filed 2016-02-19 | |||
| 2013-12-31 | $124.00M 10-K · filed 2015-02-27 | |||
| 2012-12-31 | $163.00M 10-K · filed 2014-02-21 | |||
| 2011-12-31 | $147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $147.00M derived: sum of 2 quarters · filed 2013-02-15 | $647.00M 10-K · filed 2013-02-15 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $500.00M 10-Q · filed 2011-11-04 | ||
| 2011-06-30 | $500.00M 10-Q · filed 2011-08-04 | |||
| 2010-12-31 | $160.00M 10-K · filed 2013-02-15 | |||
| 2009-12-31 | $39.00M 10-K · filed 2012-02-21 | |||
| 2008-12-31 | $121.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |